WAVE Life Sciences Ltd WVE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if WVE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $5.09
- Day Range
- $4.97–5.22
- 52-Week Range
- $3.15–7.66
- Bid/Ask
- $4.98 / $5.00
- Market Cap
- $612.64 Mil
- Volume/Avg
- 310,996 / 937,613
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 268
- Website
- https://www.wavelifesciences.com
Comparables
Valuation
|
Metric
|
WVE
|
ACRS
|
VCYT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 26.28 |
Price/Book Value | 14.55 | 0.55 | 1.39 |
Price/Sales | 4.53 | 2.73 | 3.99 |
Price/Cash Flow | — | — | 29.77 |
Price/Earnings
WVE
ACRS
VCYT
Financial Strength
|
Metric
|
WVE
|
ACRS
|
VCYT
|
|---|---|---|---|
Quick Ratio | 1.19 | 3.86 | 4.19 |
Current Ratio | 1.26 | 4.16 | 4.66 |
Interest Coverage | — | — | −5,596.07 |
Quick Ratio
WVE
ACRS
VCYT
Profitability
|
Metric
|
WVE
|
ACRS
|
VCYT
|
|---|---|---|---|
Return on Assets (Normalized) | −21.38% | −38.26% | 7.85% |
Return on Equity (Normalized) | — | −50.08% | 8.41% |
Return on Invested Capital (Normalized) | −650.48% | −49.93% | 7.64% |
Return on Assets
WVE
ACRS
VCYT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jlcxwfmkq | Vgmkc | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vjcqkkgz | Tlsmm | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wvqvybvlt | Dtpmxr | $99.6 Bil | |
MRNA
| Moderna Inc | Mmycmqm | Kmbh | $38.8 Bil | |
ARGX
| argenx SE ADR | Dppbdzpn | Rztx | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Vwmxbpjfb | Mkg | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Spycdvl | Gccbm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ykhnxqby | Bljhm | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jttwrfwh | Nqrfrw | $12.4 Bil | |
INCY
| Incyte Corp | Hthllkvs | Mymscy | $11.9 Bil |